Samchundang Pharm Signs Exclusive License Agreement for Oral GLP-1 in 11 European Countries
Upfront Payment and Milestones Total 50.8 Billion Won
Limit-Up Close on the 26th
Samchundang Pharm announced on the 26th that it has signed an exclusive license and commercialization definitive agreement for the orally administered GLP-1 (generic versions of Rybelsus for diabetes treatment and Wegovy for obesity treatment), which it is developing with a global pharmaceutical company based in Europe, covering 11 countries including the United Kingdom.
The total amount of the upfront payment and milestones (stage-based technology fees) is 30 million euros (approximately 50.8 billion won).
In the European market, which is centered on tenders, the company has finalized a profit-sharing structure under which it will receive 60% of the net profit from product sales.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, on the same day, Samchundang Pharm closed trading on the KOSDAQ market at 757,000 won, up 174,000 won (29.85%) from the previous day.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.